Details of the Drug

General Information of Drug (ID: DMPWB7T)

• Drug Name: Maprotiline
• Synonyms: Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Major depressive disorder	6A70.3	Approved	[2]
Mixed anxiety and depressive disorder	N.A.	Investigative	[1]

• Therapeutic Class: Antidepressants
• Affected Organisms: Humans and other mammals
• ATC Code:
  N06AA21: Maprotiline
  N06AA: Non-selective monoamine reuptake inhibitors
  N06A: ANTIDEPRESSANTS
  N06: PSYCHOANALEPTICS
  N: NERVOUS SYSTEM
  N06AA21: Maprotiline
  N06AA: Non-selective monoamine reuptake inhibitors
  N06A: ANTIDEPRESSANTS
  N06: PSYCHOANALEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 277.4
  Logarithm of the Partition Coefficient (xlogp); 4.6
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: 68% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [5]
  Elimination: 3% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 51 hours [5]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.5868 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.11% [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 45 L/kg [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 3.134 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Poisoning and toxicity	Not Available	CYP2D6	OTZJC802	[7]

• Chemical Identifiers:
  Formula: C20H23N
  IUPAC Name: N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine
  Canonical SMILES: CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
  InChI: InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
  InChIKey: QSLMDECMDJKHMQ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4011
  ChEBI ID: CHEBI:6690
  CAS Number: 10262-69-8
  UNII: 2U1W68TROF
  DrugBank ID: DB00934
  TTD ID: D03KQF
  VARIDT ID: DR00515
  INTEDE ID: DR1004
  ACDINA ID: D00383
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Maprotiline

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Maprotiline and Sertraline.	Depression [6A70-6A7Z]	[11]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Maprotiline and Vilazodone.	Depression [6A70-6A7Z]	[11]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Maprotiline and Nefazodone.	Depression [6A70-6A7Z]	[11]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Maprotiline and Selegiline.	Depression [6A70-6A7Z]	[12]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Maprotiline and Vortioxetine.	Depression [6A70-6A7Z]	[11]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Maprotiline and Isocarboxazid.	Depression [6A70-6A7Z]	[12]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Maprotiline and Milnacipran.	Depression [6A70-6A7Z]	[11]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Escitalopram.	Depression [6A70-6A7Z]	[13]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Maprotiline and Desvenlafaxine.	Depression [6A70-6A7Z]	[11]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Doxepin.	Depression [6A70-6A7Z]	[14]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Maprotiline and Esketamine.	Depression [6A70-6A7Z]	[15]

Coadministration of a Drug Treating the Disease Different from Maprotiline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Maprotiline and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[12]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Ivosidenib.	Acute myeloid leukaemia [2A60]	[16]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Midostaurin.	Acute myeloid leukaemia [2A60]	[13]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Idarubicin.	Acute myeloid leukaemia [2A60]	[13]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Gilteritinib.	Acute myeloid leukaemia [2A60]	[17]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Maprotiline and Oliceridine.	Acute pain [MG31]	[18]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Memantine.	Alzheimer disease [8A20]	[19]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Maprotiline when combined with Rivastigmine.	Alzheimer disease [8A20]	[20]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Ivabradine.	Angina pectoris [BA40]	[21]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Bepridil.	Angina pectoris [BA40]	[13]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Dronedarone.	Angina pectoris [BA40]	[13]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[22]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Cilostazol.	Arterial occlusive disease [BD40]	[13]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Posaconazole.	Aspergillosis [1F20]	[13]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Levalbuterol.	Asthma [CA23]	[23]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Pirbuterol.	Asthma [CA23]	[24]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Salbutamol.	Asthma [CA23]	[23]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Formoterol.	Asthma [CA23]	[24]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[21]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[19]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Maprotiline and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[13]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Telithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Retigabine.	Behcet disease [4A62]	[13]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Cariprazine.	Bipolar disorder [6A60]	[19]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Eribulin.	Breast cancer [2C60-2C6Y]	[13]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Lapatinib.	Breast cancer [2C60-2C6Y]	[13]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Maprotiline when combined with Acetylcholine.	Cataract [9B10]	[26]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[27]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[28]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[28]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[28]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Maprotiline and Dihydrocodeine.	Chronic pain [MG30]	[18]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Maprotiline and Levomilnacipran.	Chronic pain [MG30]	[11]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Isoproterenol.	Conduction disorder [BC63]	[23]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Halothane.	Corneal disease [9A76-9A78]	[13]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Sevoflurane.	Corneal disease [9A76-9A78]	[13]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Probucol.	Coronary atherosclerosis [BA80]	[13]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Pasireotide.	Cushing syndrome [5A70]	[13]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Osilodrostat.	Cushing syndrome [5A70]	[21]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Mepenzolate.	Digestive system disease [DE2Z]	[19]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Maprotiline and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[29]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Oxybutynine.	Discovery agent [N.A.]	[19]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[13]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Deutetrabenazine.	Dystonic disorder [8A02]	[30]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Ingrezza.	Dystonic disorder [8A02]	[31]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Solifenacin.	Functional bladder disorder [GC50]	[19]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Maprotiline caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[32]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Tolterodine.	Functional bladder disorder [GC50]	[19]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Ketoconazole.	Fungal infection [1F29-1F2F]	[13]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Maprotiline when combined with Pilocarpine.	Glaucoma [9C61]	[26]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Maprotiline and Procarbazine.	Hodgkin lymphoma [2B30]	[12]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Maprotiline caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Maprotiline caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[36]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[19]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Maprotiline caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[37]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Maprotiline and ITI-007.	Insomnia [7A00-7A0Z]	[19]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Maprotiline and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[13]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Maprotiline when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[20]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Maprotiline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[21]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Crizotinib.	Lung cancer [2C25]	[38]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Ceritinib.	Lung cancer [2C25]	[13]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Maprotiline caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Osimertinib.	Lung cancer [2C25]	[40]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Selpercatinib.	Lung cancer [2C25]	[21]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Lumefantrine.	Malaria [1F40-1F45]	[15]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Halofantrine.	Malaria [1F40-1F45]	[41]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Hydroxychloroquine.	Malaria [1F40-1F45]	[42]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Primaquine.	Malaria [1F40-1F45]	[13]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[21]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[43]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Vemurafenib.	Melanoma [2C30]	[13]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and LGX818.	Melanoma [2C30]	[44]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Maprotiline and Flibanserin.	Mood disorder [6A60-6E23]	[45]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Maprotiline and Thalidomide.	Multiple myeloma [2A83]	[46]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Siponimod.	Multiple sclerosis [8A40]	[15]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Maprotiline and Fingolimod.	Multiple sclerosis [8A40]	[13]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Maprotiline and Ozanimod.	Multiple sclerosis [8A40]	[47]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Romidepsin.	Mycosis fungoides [2B01]	[13]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Maprotiline caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[21]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Nilotinib.	Myeloproliferative neoplasm [2A20]	[13]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Dasatinib.	Myeloproliferative neoplasm [2A20]	[48]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Phenindamine.	Nasopharyngitis [CA00]	[19]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Dimenhydrinate.	Nausea/vomiting [MD90]	[19]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Promethazine.	Nausea/vomiting [MD90]	[19]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Maprotiline caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[49]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Cyclizine.	Nausea/vomiting [MD90]	[19]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Maprotiline and Bupropion.	Nicotine use disorder [6C4A]	[13]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Entrectinib.	Non-small cell lung cancer [2C25]	[15]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Maprotiline caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[50]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Maprotiline and Dexfenfluramine.	Obesity [5B80-5B81]	[11]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Levomethadyl Acetate.	Opioid use disorder [6C43]	[21]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Maprotiline and Apraclonidine.	Optic nerve disorder [9C40]	[51]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Rucaparib.	Ovarian cancer [2C73]	[13]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Maprotiline and Oxymorphone.	Pain [MG30-MG3Z]	[18]
Dezocine	DMJDB0Y	Moderate	Additive serotonergic effects by the combination of Maprotiline and Dezocine.	Pain [MG30-MG3Z]	[18]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Flavoxate.	Pain [MG30-MG3Z]	[19]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Maprotiline and Hydrocodone.	Pain [MG30-MG3Z]	[18]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Triclabendazole.	Parasitic worm infestation [1F90]	[13]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Maprotiline and Safinamide.	Parkinsonism [8A00]	[47]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Maprotiline and Rasagiline.	Parkinsonism [8A00]	[12]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Pimavanserin.	Parkinsonism [8A00]	[52]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Orphenadrine.	Parkinsonism [8A00]	[19]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Methylscopolamine.	Peptic ulcer [DA61]	[19]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[53]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Lefamulin.	Pneumonia [CA40]	[54]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Degarelix.	Prostate cancer [2C82]	[21]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Maprotiline caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[55]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Enzalutamide.	Prostate cancer [2C82]	[21]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Bicalutamide.	Prostate cancer [2C82]	[21]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Levomepromazine.	Psychotic disorder [6A20-6A25]	[19]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[56]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Quetiapine.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Paliperidone.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Molindone.	Schizophrenia [6A20]	[19]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Thiothixene.	Schizophrenia [6A20]	[19]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Amisulpride.	Schizophrenia [6A20]	[57]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Pimozide.	Schizophrenia [6A20]	[21]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Maprotiline and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[13]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[13]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[21]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[13]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Lenvatinib.	Thyroid cancer [2D10]	[13]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Cabozantinib.	Thyroid cancer [2D10]	[21]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[14]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Maprotiline and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[19]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Procainamide.	Ventricular tachyarrhythmia [BC71]	[13]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Propafenone.	Ventricular tachyarrhythmia [BC71]	[13]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Maprotiline and Flecainide.	Ventricular tachyarrhythmia [BC71]	[13]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Maprotiline and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[13]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Maprotiline 50 mg tablet	50 mg	Oral Tablet	Oral
Maprotiline 25 mg tablet	25 mg	Oral Tablet	Oral
Maprotiline 75 mg tablet	75 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Maprotiline FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [8] Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
• [9] Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
• [10] The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer. 2011 Apr 1;128(7):1712-23. doi: 10.1002/ijc.25477. Epub 2010 May 25.
• [11] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [12] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
• [13] Canadian Pharmacists Association.
• [14] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [17] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [18] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [19] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [20] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [21] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [22] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [23] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [25] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [26] Multum Information Services, Inc. Expert Review Panel.
• [27] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [28] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [29] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
• [30] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [31] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [32] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [33] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [34] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [35] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [36] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [37] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [38] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [39] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [40] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [41] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [42] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [43] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [44] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [45] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [46] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [47] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [48] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [49] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [50] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [51] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [52] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [53] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [54] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [55] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [56] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [57] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.